DATASET 2026-08-0941 PROGRAMS INDEXEDTIRZEPATIDE ALL-IN $215–$597/MOEVERY FIGURE CAPTURE-DATED & SOURCE-LINKED
TopGLP1Providers.comverified price index
VERIFIED 2026-08-09
NexLife T $215✓Yucca Health T $258✓IVIM Health T $278✓Mochi Health T $278✓ShedRx T $289✓Found T $289✓SkinnyRx T $299✓OrderlyMeds T $299✓Amble Health T $300✓Henry Meds T $349✓TrimRx T $349✓Lavender Sky Health T $352✓Fridays T $359✓MEDVi T $399✓Remedy Meds T $399✓Eden T $408✓LifeMD T $597✓Oak Longevity S $133✓Yucca Health S $146✓IVIM Health S $149✓OrderlyMeds S $149✓NexLife S $165✓Lavender Sky Health S $174✓Zepbound vials $449✓Wegovy $349✓Oral Wegovy from $149✓NexLife T $215✓Yucca Health T $258✓IVIM Health T $278✓Mochi Health T $278✓ShedRx T $289✓Found T $289✓SkinnyRx T $299✓OrderlyMeds T $299✓Amble Health T $300✓Henry Meds T $349✓TrimRx T $349✓Lavender Sky Health T $352✓Fridays T $359✓MEDVi T $399✓Remedy Meds T $399✓Eden T $408✓LifeMD T $597✓Oak Longevity S $133✓Yucca Health S $146✓IVIM Health S $149✓OrderlyMeds S $149✓NexLife S $165✓Lavender Sky Health S $174✓Zepbound vials $449✓Wegovy $349✓Oral Wegovy from $149✓

The two molecules behind every program

This market is two medications wearing forty storefronts. Tirzepatide — the stronger trial averages, the higher prices (brand $299–$449, compounded from $215) — carries about 60% of the category's search interest and 60% of this site. Semaglutide — cheaper everywhere (brand $349, compounded from $133), with the only approved oral option (from $149).

Updated 2026-08-10 · figures captured 2026-08-09 · how we verify

Tirzepatide

Zepbound & Mounjaro; SURMOUNT evidence; the $215–$597 compounded market; the 503A lane.

$215+

Semaglutide

Wegovy, Ozempic, the oral pill; the shrinking compounded discount; the safety question sorted.

$133+

Head-to-head, in the only randomized comparison that matters (SURMOUNT-5, NEJM 2025): tirzepatide averaged roughly 20% body-weight reduction versus semaglutide's 14% at maximum tolerated doses — about 47% greater relative loss — at a real price premium at every layer of the market. Whether that trade is worth it for you is a clinical and financial question in that order: prescriber first, then the cost answer and your own math.